Home›Companies›Biotech & Pharma›Sensible Bio

Sensible Biotechnologies, Inc.

Develops a cell-based platform to produce mRNA for medicines.

Updated Nov 9, 2026·Latest SEC filing Sep 2, 2026·Suggest an edit

About Sensible Bio

Sensible Bio is a private company based in Oxford, Oxfordshire, United Kingdom, incorporated in 2021 in Delaware. It has reported $15,347,941 raised in two offerings on Form D since February 2023. Its chief executive is Miroslav Gasparek.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Aug 17, 2026Sep 2, 2026$13,518,941of $15.0M target15$901KEquityRule 506(b)Form D ↗
Feb 6, 2023Feb 21, 2023$1,829,000of $3.0M target18$101KEquityRule 506(b)Form D ↗
Total, two offerings$15,347,941

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Sensible Bio's Form D filed Sep 2, 2026.

Marian Kupculak
Marian Kupculak
CSO, Co-Founder and director
On every Form D that Sensible Bio has filed: 2 filings, from Feb 21, 2023 to Sep 2, 2026.
Miroslav Gasparek
Miroslav Gasparek
CEO, Co-Founder and director
On every Form D that Sensible Bio has filed: 2 filings, from Feb 21, 2023 to Sep 2, 2026.
Joel Schoppig
Joel Schoppig
Partner, Oxford Science Enterprises and director
First appears on the Form D that Sensible Bio filed on September 2, 2026; on 1 of its 2 filings.
Vishal Gulati
Vishal Gulati
Founder and Managing Partner, Recode Ventures, director
First appears on the Form D that Sensible Bio filed on September 2, 2026; on 1 of its 2 filings.

Sources

  1. SECSensible Biotechnologies, Inc. filing history
  2. CompanyCookie policy
  3. PressPre-seed financing announcement
  4. InvestorBacked portfolio profile
  5. Press2026 financing announcement
  6. CompanyPrivacy policy